CN100338061C - 炔－芳基磷酸二酯酶－4抑制剂 - Google Patents

炔－芳基磷酸二酯酶－4抑制剂 Download PDF

Info

Publication number
CN100338061C
CN100338061C CNB028213270A CN02821327A CN100338061C CN 100338061 C CN100338061 C CN 100338061C CN B028213270 A CNB028213270 A CN B028213270A CN 02821327 A CN02821327 A CN 02821327A CN 100338061 C CN100338061 C CN 100338061C
Authority
CN
China
Prior art keywords
alkyl
phenyl
dihydro
naphthyridine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028213270A
Other languages
English (en)
Chinese (zh)
Other versions
CN1639161A (zh
Inventor
D·瓜
M·吉拉尔
P·哈梅尔
S·拉利伯特
R·弗里森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CN1639161A publication Critical patent/CN1639161A/zh
Application granted granted Critical
Publication of CN100338061C publication Critical patent/CN100338061C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
CNB028213270A 2001-08-29 2002-08-27 炔－芳基磷酸二酯酶－4抑制剂 Expired - Fee Related CN100338061C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31609301P 2001-08-29 2001-08-29
US60/316,093 2001-08-29

Publications (2)

Publication Number Publication Date
CN1639161A CN1639161A (zh) 2005-07-13
CN100338061C true CN100338061C (zh) 2007-09-19

Family

ID=23227432

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028213270A Expired - Fee Related CN100338061C (zh) 2001-08-29 2002-08-27 炔－芳基磷酸二酯酶－4抑制剂

Country Status (28)

Country Link
US (2) US6743802B2 (enExample)
EP (2) EP1436290B8 (enExample)
JP (1) JP4157035B2 (enExample)
KR (1) KR100928849B1 (enExample)
CN (1) CN100338061C (enExample)
AR (1) AR036365A1 (enExample)
AU (1) AU2002322940B2 (enExample)
BR (1) BR0212042A (enExample)
CA (1) CA2456817C (enExample)
DO (1) DOP2002000456A (enExample)
EA (1) EA006800B1 (enExample)
EC (1) ECSP044992A (enExample)
GE (1) GEP20063805B (enExample)
HK (1) HK1080073B (enExample)
HR (1) HRP20040151A2 (enExample)
HU (1) HUP0401729A3 (enExample)
IL (1) IL160213A0 (enExample)
IS (1) IS7138A (enExample)
JO (1) JO2311B1 (enExample)
MX (1) MXPA04001889A (enExample)
NO (1) NO330521B1 (enExample)
NZ (1) NZ530931A (enExample)
PE (1) PE20030416A1 (enExample)
PL (1) PL367716A1 (enExample)
RS (1) RS17004A (enExample)
UA (1) UA75957C2 (enExample)
WO (1) WO2003018579A1 (enExample)
ZA (1) ZA200400952B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
AU2003291418A1 (en) * 2002-11-15 2004-06-15 Merck And Co., Inc. Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
EP1592419A1 (en) * 2002-11-22 2005-11-09 Merck Frosst Canada & Co. Use of phosphodiesterase-4 inhibitors as enhancers of cognition
AR042194A1 (es) * 2002-11-22 2005-06-15 Merck & Co Inc Metodo para preparar inhibidores de fosfodiesterasa - 4
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1742628A4 (en) * 2004-04-26 2009-06-03 Merck Frosst Canada Ltd ALTERNATIVE FORMS OF PHOSPHODIESTERASE-4-HEMMER N-CYCLOPROPYL-1- (3-1 / 4 (1-OXIDOPYRIDIN-3-YL) ETHYNYL-PHENYL) -4-OXO-1,4-DIYHDRO-1,8-NAPHTHYRIDINE- 3-carboxyamide
JP4264388B2 (ja) * 2004-07-01 2009-05-13 富士通株式会社 半導体チップの接合方法および接合装置
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7687490B2 (en) * 2005-04-12 2010-03-30 Meiji Seika Kaisha, Ltd. 2-thioethenyl substituted carbapenem derivatives
JP2006016407A (ja) * 2005-06-15 2006-01-19 Yamaha Motor Co Ltd ホスホジエステラーゼ阻害剤
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009509980A (ja) * 2005-09-28 2009-03-12 メルク フロスト カナダ リミテツド 篩分けされたラクトースを含むエアゾール粉末製剤
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0619785A2 (pt) 2005-12-13 2011-10-18 Wyeth Corp composto, composição e método para o tratamento de um transtorno proliferativo e método de prepraração
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US20080254029A1 (en) * 2007-04-11 2008-10-16 Alcon Research, Ltd. Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
AU2008266960A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
KR20100072295A (ko) * 2007-10-25 2010-06-30 머크 프로스트 캐나다 리미티드 병용 요법
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103214478B (zh) * 2012-01-19 2015-07-15 山东轩竹医药科技有限公司 吡啶并氧代哒嗪衍生物
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
AU2019417718A1 (en) 2018-12-28 2021-07-08 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with Arachidonate 15-Lipoxygenase (ALOX15) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239478A (zh) * 1997-08-06 1999-12-22 三得利株式会社 作为iv型磷酸二酯酶抑制剂的1－芳基－1,8－二氮杂萘－4－酮衍生物
WO2000009504A1 (en) * 1998-08-11 2000-02-24 Pfizer Products Inc. Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
CN1256693A (zh) * 1998-01-29 2000-06-14 三得利株式会社 作为ⅳ型磷酸二酯酶抑制剂的1－环烷基－1,8－二氮杂萘-4-酮衍生物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
ES2092729T3 (es) 1992-07-01 1996-12-01 Hoechst Ag Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
ATE260911T1 (de) 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0765867A1 (de) 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19622370A1 (de) 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
PL334059A1 (en) 1996-12-11 2000-01-31 Basf Ag Ketone benzamides useful as calpain inhibitors
AU8780898A (en) 1997-08-20 1999-03-08 First Data Corporation Interactive tax payment system
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239478A (zh) * 1997-08-06 1999-12-22 三得利株式会社 作为iv型磷酸二酯酶抑制剂的1－芳基－1,8－二氮杂萘－4－酮衍生物
CN1256693A (zh) * 1998-01-29 2000-06-14 三得利株式会社 作为ⅳ型磷酸二酯酶抑制剂的1－环烷基－1,8－二氮杂萘-4-酮衍生物
WO2000009504A1 (en) * 1998-08-11 2000-02-24 Pfizer Products Inc. Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Substituted 1,8-Naphthyridin-281H)-ones as SelectivePhosphodiesterase IV Inhibitors. MATSUURA A ET AL,BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN),Vol.498.503 1994 *

Also Published As

Publication number Publication date
NO20041293L (no) 2004-05-27
CN1639161A (zh) 2005-07-13
EA200400361A1 (ru) 2004-08-26
EP2305677A1 (en) 2011-04-06
NO330521B1 (no) 2011-05-09
HRP20040151A2 (en) 2006-05-31
EP1436290B1 (en) 2013-09-18
RS17004A (sr) 2007-02-05
IL160213A0 (en) 2004-07-25
HK1080073B (zh) 2008-08-08
NO20041293D0 (no) 2004-03-26
BR0212042A (pt) 2004-08-17
AU2002322940B2 (en) 2007-03-01
WO2003018579A1 (en) 2003-03-06
IS7138A (is) 2004-01-30
EP1436290A1 (en) 2004-07-14
KR20040034672A (ko) 2004-04-28
MXPA04001889A (es) 2004-06-15
PL367716A1 (en) 2005-03-07
KR100928849B1 (ko) 2009-11-30
JO2311B1 (en) 2005-09-12
GEP20063805B (en) 2006-04-25
EA006800B1 (ru) 2006-04-28
JP2005508313A (ja) 2005-03-31
ZA200400952B (en) 2004-10-22
US6743802B2 (en) 2004-06-01
EP1436290B8 (en) 2013-12-04
HUP0401729A2 (hu) 2004-12-28
ECSP044992A (es) 2004-04-28
CA2456817C (en) 2010-11-30
UA75957C2 (en) 2006-06-15
HUP0401729A3 (en) 2012-09-28
CA2456817A1 (en) 2003-03-06
HK1080073A1 (zh) 2006-04-21
PE20030416A1 (es) 2003-05-15
NZ530931A (en) 2005-12-23
US20030114478A1 (en) 2003-06-19
US20050070569A1 (en) 2005-03-31
AR036365A1 (es) 2004-09-01
JP4157035B2 (ja) 2008-09-24
DOP2002000456A (es) 2003-02-28

Similar Documents

Publication Publication Date Title
CN100338061C (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1191249C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
CN1046725C (zh) 稠合的咪唑化合物,它们的制备和应用
CN1221534C (zh) 取代的8－芳基喹啉磷酸二酯酶－4抑制剂
CN1103770C (zh) 喹喔啉二酮化合物
CN1738819A (zh) 4－氧代－1－(3－取代苯基)－1,4－二氢－1,8－萘啶－3－甲酰胺磷酸二酯酶－4抑制剂
CN1671696A (zh) 激酶抑制剂
CN1674898A (zh) 作为促旋酶和 /或拓扑异构酶 i v的抑制剂用于治疗细菌感染的 2 －脲基－6－杂芳基－3 h－苯并咪唑－4－羧酸衍生物和相关化合物
CN1745077A (zh) 促旋酶抑制剂及其用途
CN1040795A (zh) 三唑类抗霉菌剂的制备方法
CN1059143A (zh) 吡唑并吡啶化合物及其制备方法
CN1942465A (zh) Akt活性抑制剂
CN1374953A (zh) 含氮的6－员芳香环化合物
CN1823064A (zh) 用于治疗与gsk3有关的病症的2－芳基氨基－嘧啶
CN1913778A (zh) 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂
CN1681805A (zh) 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
CN1639135A (zh) N－芳基－2－噁唑烷酮－5－酰胺及其衍生物和它们作为抗菌剂的用途
CN1139928A (zh) 新化合物
CN1503673A (zh) 消炎药
CN1202171A (zh) 吡啶并[2,3－d]嘧啶衍生物及其医药组合物
CN1826334A (zh) 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
CN1224624C (zh) 1,8－二氮杂萘－2(1h)－酮衍生物
CN1551769A (zh) 被取代的8-芳基喹啉磷酸二酯酶-4抑制剂
CN1812787A (zh) 8－(3－联芳基)苯基喹啉磷酸二酯酶－4抑制剂
CN1829519A (zh) 二苯基取代的环烷烃类,含有它们的组合物和应用的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MACPHER ROSSITER CANADA CO., LTD.

Free format text: FORMER OWNER: MCFROST (CANADA) CO.

Effective date: 20051223

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051223

Address after: Quebec

Applicant after: Merck Frosst Canada Ltd.

Address before: Quebec

Applicant before: Merck Frosst Canada & Co.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080073

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1080073

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: MERCK (CANADA) CO., LTD.

Free format text: FORMER NAME: MERCK FROSST CANADA LTD.

CP01 Change in the name or title of a patent holder

Address after: Quebec

Patentee after: Merck Canada Inc.

Address before: Quebec

Patentee before: Merck Frosst Canada Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070919

Termination date: 20190827

CF01 Termination of patent right due to non-payment of annual fee